Human BCR-ABL Fusion Gene Mutation Detection Kit (Real-time PCR)

NCCN: qPCR monitoring recommended for patients with chronic myeloid leukaemia

The NCCN clinical practice guidelines for chronic myelogenous leukemia in the United States recommend monthly qPCR surveillance and imitation of treatment if BCR-ABL 1 increases to >1%.

A fusion gene formed by translocation of ABL photo-oncogene on chromosome 9 and BCR gene on chromosome 24 in human cells. It can cause continuous activation of protein kinase, resulting in excessive proliferation of white blood cells and chronic myelogenous leukemia.

The detection of BCR-ABL 190 and 210 fusion genes can be used for the differential diagnosis of CML. To guide the use of targeted therapy drugs such as imatinib; Prognostic judgement and treatment effect monitoring.

[Intended Use]

ultrassay BCR-ABL Real-time PCR test kit is used for in vitro qualitative detection of BCR-ABL 190 and 210 fusion genes in human bone marrow samples, providing an auxiliary means for the diagnosis of leukemia patients. The test results are for clinical reference only, and the final diagnosis should be considered in conjunction with other clinical indicators.


  • Specificity: No cross-reaction with other fusion genes
  • Sensitivity: Limit of detection to 1000 copies/reaction.
  • Reliability: Internal reference, blank control, positive control of the whole process quality control.